Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M11D1 plus chemotherapy or venetoclax + azacitidine in AML
CTR20254465Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M11D1 in acute myeloid leukemia (AML), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
BL-M11D1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20254465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254465.